Journal of Veterinary Clinics (한국임상수의학회지)

The Korean Society of Veterinary Clinics (한국임상수의학회)
권호 표지

Effect of Interleukin-2 on Antitumor Response Against Ultraviolet Radiation-Induced Fibrosarcoma in Mice

마우스에서 자외선 조사에 의해 유도된 종양세포에 대한 Interleukin-2의 항암효과

  • 권오덕 (전북대학교 수의과대학, 생체안정성연구소)
  • Published : 2001.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Recombinant interleukin-2 (IL-2) has demonstrated as an antineoplastic agent in mice and human, but the relatively low response rates observed in clinical trials. Therefore, the present study was undertaken in order to evaluate therapeutic activities of IL-2 for the establishment of therapeutic applications. At the onset of the experiment, normal C3H/HeN mice were injected with $3{\times}10^6$ RD-995 tumor cells, murine ultraviolet radiation-induced fibrosarcoma, subcutaneously. Beginning on day 25, experimental groups were treated with a 5-day course of IL-2 (subcutaneous injection of 30,000 IU every 12 hours for 5 days). The result of this experiment revealed that RD-995 tumor grew progressively in control mice. Subcutaneous IL-2 therapy decreased tumor growth until day 23, then the tumor grew progressively. No significant difference in the survival of IL-2 therapy decreased tumor growth until day 23, then the tumor grew progressively. No significant difference in the survival of IL-2 therapy decreased tumor growth until day 23, then the tumor grew progressively. No significant difference in the survival of IL-2 treated mice were observed compared with the control mice.

Keywords

References

  1. Clin Pharma-cokinet v.27 Effects of route and formulation on clinical pharmacokinetics of interleukin-2 Anderson PM;Sorenson MA
  2. Cancer Res v.50 Correlation between clinical response to interleukin-2 therapy and sustained production of tumor necrosis factor Blay JY;Favrot MC;Negricr S;Combaret V;Chouaib S;Mercatello A;Kaemmerlen P;Franks CR;Phillip T
  3. Cancer Res v.50 Adoptive immunotherapy of human cancer. The cytokine cascade and monocyte activation following high-dose interleukin-2 bolus treatment Boccoli G;Masciulli R;Ruggeri EM;Carlini P;Giannella G;Montesoro E;Mastroberardino G;Isacchi G;Testa U;Calabresi F(et al.)
  4. Cancer Immunol Immunother v.49 Killing of Fas ligand-resistant renal carcioma cells by interleukin-2 and BCG-activated effector cells Brandau S;Suttmann H;Flad HD;Jocham D;Bohle A
  5. Blood v.93 Interleukin-2-activated rat natural killer cells express inducible nitric oxide synthase that contributes to cytotoxic function and interferon-gamma production Cifone MG;D'Alo S;Parroni R;Millimaggi D;Biordi L;Martinotti S;Santoni A
  6. Clin Cancer Res v.6 Phase II trial of interleukin 2, interferon alpha, and 5- fluorouracil in metastatic renal cell cancer: a cytokine working group study Dutcher JP;Logan T;Gordon M;Sosman J;Weiss G;Margolin K;Plasse T;Mier J;Lotze M;Clark J;Atkins M
  7. Cancer Res v.48 Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells Gelmo BT;Palladino MA Jr;Jeffe HS;Espevik TP;Rayner AA
  8. Biochem Biophys Res Commun v.157 A cytotoxic activated macrophage effector molecule Hibbs JB Jr;Taintor RR;Vavrin Z;Rachlin C;Nitric oxide
  9. J Clin Invest v.89 Evidence for cytokine inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy Hibbs JB Jr;Westenfelder C;Taintor RR;Vavrin Z;Kablitz C;Baranowski RL;Ward JH;Menloce RL;McMurry MP;Kushner JP;Samlowski WE
  10. J Urol v.160 Nitric oxide synthase activity in human renal cell carcinoma Jansson OT;Morcos E;Brundin L;Bergerheim US;Adolfsson J;Wiklund NP
  11. Scand J Immunol v.52 Interleukin-2-induced nitric oxide synthase and nuclear factor-kappa B activity in activated natural killer cells and the production of interferon-gamma Jyothi MD;Khar A
  12. J Immunol v.143 Induction of endogeneous cytokine mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients Kasid A;Director EP;Rosenberg SA
  13. Cancer Res v.37 Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains Kripke ML
  14. Anticancer Res v.20 Effect of GM-CSF and IL-2 co-expression on the anti-tumor immune response Lee SG;Heo DS;Yoon SJ;Jee YS;Kang JO;Kim K;Kim CD;Sung MW;Kim NK
  15. Cancer Res v.41 Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor Lotze MT;Grimn EA;Mazumder A;Strausser JI;Rosenberg SA
  16. Semin Oncol v.27 Interleukin-2 in the treatment of renal cancer Margolin KA
  17. Immunol v.172 Human interleukin-2 molecular biology, physiology and clinical possibilities Mertelsmann R;Welte K
  18. J Clin Immuno v.8 Induction of circulating tumor necrosis factor (TNF a) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients Mier JW;Vachino G;Van Der Meer JWM;Numerof RP;Adams S;Cannon JG;Bernheim HA;Atkins MB;Parkinson DR;Dinarello CA
  19. Cancer Res v.46 Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice Papa MZ;Vetto JT;Ettinghausen SE;Mule JJ;Rosenberg SA
  20. Fundamental immunology(3rd ed) T-cell derived cytokines and their receptors Paul WE
  21. Postepy Hig Med Dosw v.49 Biological properties and therapeutic use of interleukin 2 (IL-2) Robak T
  22. Ann Int Med v.108 New approach to the immunotherapy of cancer using interleukin-2 Rosenberg SA;Lotze MT;Mule JJ
  23. J Immunother v.18 Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL-2 treatment of mice Samlowski WE;Yim CY;McGregor JR;Kwon OD;Gonzales S;Hibbs JB Jr
  24. The cytokine handbook Interleukin-2 Thomson A
  25. Drugs v.46 Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer Whittington R;Faulds D
  26. Cancer Res v.55 Macrophage nitric oxide synthesis delays progression of ultraviolet light induced murine skin cancers Yim CY;Bastian NR;Smith JC;Hibbs JB Jr;Samlowski WE
  27. Korean J Intern Med v.11 Effects of nitric oxide (NO) synthesis inhibition on antitumor responses during interleukin-2 (IL-2) treatment of mice Yim CY;Lee CW;Choi SM;Park SS;Lee SJ;Kim JH;Song JS;Yoo WH;Kwak JY;Sohn MH
  28. J Immunol v.155 Nitric oxide synthesis contributes to IL-2-induced antitumor response against intraperitoneal Meth A tumor Yim CY;McGregor JR;Kwon OD;Bastian NR;Rees M;Mori M;Hibbs JB Jr;Samlowski WE
  29. 한국임상수의학회지 v.17 마우스에서 Meth-A 종양세포에 대한 interleukin-2의 항암효과 권오덕
  30. Harrison's 내과학 해리슨내과학편찬위원회